Although we did identify 7 unique mutations (MRLP37, CEP152, PYGB, TUBGCP6, CAPN2, XRRA1, and SPSB2) among the 14 potentially deleterious genetic mutations in Case 1 before ADI-PEG20 treatment (Supplementary Fig. 1), these mutations were not frequently reported in AML patients, and they were not found in the non-responders or in the normal hematopoietic cells from Case 1. The gene discussed is CAPN2; the disease is acute myeloid leukemia.